Can a patient with a seizure disorder receive the shingles vaccine (live attenuated zoster vaccine Zostavax or recombinant subunit vaccine Shingrix) if she meets the usual age and health criteria and is not otherwise immunocompromised?

Can a Patient with a Seizure Disorder Receive the Shingles Vaccine?

Yes, a patient with a seizure disorder can safely receive the shingles vaccine—specifically, she should receive Shingrix (recombinant zoster vaccine), not Zostavax. A seizure disorder alone does not constitute immunocompromise and is not a contraindication to either shingles vaccine.

Vaccine Selection

Shingrix is the preferred shingles vaccine for all adults ≥50 years, including those with seizure disorders. 1, 2

• Shingrix is a non-live recombinant subunit vaccine containing varicella-zoster virus glycoprotein E with AS01B adjuvant 2
• It demonstrates 97.2% efficacy against herpes zoster in adults aged ≥50 years 1
• Protection remains ≥83.3% for at least 8 years with minimal waning 1

Why Seizure Disorder Is Not a Contraindication

The only absolute contraindications to Shingrix are severe allergic reaction to a vaccine component or after a previous dose—seizure disorders are not listed as contraindications. 3

• Seizure disorders do not cause the immunosuppression that would contraindicate live vaccines 3
• The IDSA guidelines classify immunocompromised patients by CD4 counts, chemotherapy, transplant status, and biologic therapies—not by neurologic conditions 3
• Unless your patient is taking high-dose immunosuppressive medications for her seizures (which would be unusual), she is immunocompetent 3

Important Distinction: MMRV Vaccine Warning Does NOT Apply Here

The guideline warning about febrile seizures applies only to MMRV vaccine in children <4 years, not to Shingrix in adults. 3

• MMRV (measles-mumps-rubella-varicella) vaccine contains ≥7-fold more VZV than varicella vaccine and causes significantly more fever and febrile seizures when given as a first dose to children aged <4 years 3
• This pediatric vaccine concern is completely irrelevant to adult shingles vaccination 3
• Shingrix is a non-live subunit vaccine with a different mechanism and safety profile 2

Dosing Schedule

Administer Shingrix as a 2-dose series with doses given 2–6 months apart (minimum 4 weeks). 1

• Give the first dose at the next available appointment 1
• Schedule the second dose 2–6 months later 1
• If she is on antiepileptic medications, continue them without interruption—no medication holds are needed 1

Expected Side Effects

Counsel the patient that injection-site reactions and systemic symptoms are common but transient. 1

• Grade 3 injection-site reactions occur in 9.5% (vs. 0.4% placebo) 1
• Systemic symptoms (myalgia, fatigue, fever) occur in 11.4% (vs. 2.4% placebo) 1
• Most reactions resolve within approximately 4 days 1
• Serious adverse events are no different from placebo 1

Common Pitfall to Avoid

Do not confuse the patient's seizure disorder with immunocompromise or assume neurologic conditions are contraindications to vaccination. 3

• Only highly immunocompromised states (CD4 <200, active chemotherapy, high-dose biologics, recent transplant) alter vaccine recommendations 3
• Seizure medications like levetiracetam, valproate, or carbamazepine do not cause clinically significant immunosuppression 3
• The live-attenuated Zostavax is contraindicated only in immunocompromised patients, not in patients with seizure disorders 3

Why Not Zostavax?

Even though Zostavax is not contraindicated in seizure patients, Shingrix is strongly preferred due to superior efficacy. 1, 4

• Zostavax efficacy declines to only 14.1% by year 10 1
• Shingrix maintains >83% efficacy for at least 8 years 1
• Shingrix is more cost-effective than Zostavax across all age groups 4